Pfizer to Invest Over $1.26 Billion in Dublin Manufacturing Site

Reuters2022-12-01

(Reuters) - Pfizer Inc said on Thursday it plans to invest more than 1.2 billion euros ($1.26 billion) to expand manufacturing at its plant in Dublin, which would double the capacity to produce key substances used in biological drugs.

The company last year began producing an ingredient for its COVID-19 vaccine at the facility in Grange Castle, Dublin.

"This investment for non-COVID licensed and pipeline products, will help to further expand the site's broad and robust capabilities," Mike McDermott, chief global supply officer at Pfizer, said.

The move will lead to the creation of 400 to 500 new roles and add a new facility, which is due for completion in 2027, according to the company.

($1 = 0.9530 euros)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
2